Atossa Therapeutics reports Q3 EPS (5c), consensus (7c)

Ended Q3 with $94.0M of cash and cash equivalents. “Q3 was another period of significant advancement for our Company and our (Z)-endoxifen development program,” said CEO Steven Quay. “With two Phase 2 trials approaching full enrollment, we are preparing for expected data readouts in the second half of 2024. We also made important progress with our EVANGELINE study by initiating the 80mg PK run-in cohort and announced a fourth Phase 2 study in DCIS, which like our trial in mammographic breast density, is investigating Z-endoxifen in a population of women who are at high risk of developing breast cancer. We expect data from these four ongoing Phase 2 trials to further strengthen the growing body of evidence that Z-endoxifen may play an important role in both the prevention and treatment of breast cancer.”